The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...

A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab ...

Number 5: The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as ...

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes ...

Celltrion announced the FDA had approved a new formulation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab). The approval, for a 45 mg/0.5 mL solution in a single-dose vial for ...